Nanobiotix’s 13% Rally: A Speculative Spike, Not a Real Breakthrough
Nanobiotix’s 13.5% surge is hype, not proof—volatility, low earnings and a steep over‑valuation warn investors to beware the speculative bubble.
4 minutes to read
NANOBIOTIX
Nanobiotix Shares Surge 13.5% as New Corporate Update Highlights Cancer Nanomedicine Breakthroughs
Nanobiotix (NANO.PA) surges 13.5% as its NBTXR3 nanomedicine gains traction, boosting investor demand and spotlighting future cancer therapy breakthroughs.
3 minutes to read
Nanobiotix Shares Surge 12.5% as Investors Back NanoXray Cancer Innovation
Nanobiotix shares jump 12.5% as investors rally behind its NanoXray cancer‑radiotherapy platform, boosting the firm’s €938 m market cap.
3 minutes to read